Reports Q2 revenue $4M vs. $9.8M last year. CASI‘s Board of Directors has formed a special committee to evaluate Dr. He’s proposal letter dated June 21, 2024, to acquire the entire business operations of the company in China, including all license-in, distribution and related rights in Asia (excluding Japan), for an aggregate purchase price of $40M. The offer price includes assumption of up to $20M of the company’s debt.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI: